Search
Menu
Home
HTB
2012
June
HTB
June 2012
Contents
Editorial
Volume 13 Number 5/6 May/June 2012
Conference reports
18th Annual BHIVA Conference, 18-20 April 2012, UK
Half of gay men in London would chose oral PrEP to reduce risk of HIV
Recent infection is common in UK; 30% gay men aged 15-25 infected within a year of diagnosis
One third of HIV positive people at five UK clinics have symptomatic depression: link to adherence and viral suppression – 40% cases are untreated
Hodgkin’s lymphoma: survival normalises to HIV negative rates despite more advanced disease at diagnosis
Promising outcomes from laser ablative treatment of AIN2/3 to prevent anal cancer
KS in the HAART era includes patients with high CD4 and suppressed viral load: importance of KS chemotherapy for some patients in addition to ART
3rd vs 4th generation HIV testing: almost half of UK clinics out of step with national guidelines
Case reports of complications from ketamine use in two MSM on ritonavir-based combinations
Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations
Outcomes from switches to atazanavir/r in London
Intimate partner violence towards HIV positive women in the UK
13th International workshop on Clinical Pharmacology of HIV Therapy, 16-18 April 2012, Barcelona
Studies on pipeline ARVs
Washout pharmacokinetics of transplacental raltegravir in neonates
Interactions between malaria drugs and etravirine or darunavir/r
No interaction between antimalarial amodiaquine and nevirapine
Pharmacokinetics of atazanavir/ritonavir plus raltegravir
Atazanavir/ritonavir and voriconazole not to be coadministered
Milk thistle (silymarin) and darunavir/ritonavir
Echinacea and etravirine
Warfarin and ARVs: impact of African American race and ritonavir
19th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 March 2012, Seattle
HIV and the brain: longitudinal results from CHARTER and other studies
Systolic blood pressure and risk of myocardial infarction in HIV infection
Risk of non-AIDS defining malignancies and immune suppression
Renal impairment in the D:A:D study
Early data for rilpivirine long acting formulation supports further investigation for PrEP
Hormonal contraception: HIV transmission and progression rates
Darunavir use during pregnancy
Antiretrovirals
Fosamprenavir paediatric dosing approved in US for ages 4 weeks to <6 years
FDA advisory panel vote 13:1 for approval of Quad
FDA advisory hearing supports approval of tenofovir/FTC for PrEP
Treatment access
Stavudine (d4T) phase-out festival in Delhi
FDA approval of generic ARVs: nevirapine and Combivir now off-patent in the US
Pregnancy
New UK guidelines: Management of HIV infection in pregnant women (2012)
Guidelines
New UK guidelines: Treatment of HIV-1 positive adults with antiretroviral therapy (2012)
WHO guidelines for testing, counselling and treatment in serodifferent couples (April 2012): ART at CD4 >350 to reduce transmission
NICE guideline on fertility treatment proposes alternatives to sperm washing (2012)
Side effects
20% people switch Atripla due to efavirenz side effects: late switches are common
Risk factors associated with End Stage Renal Disease (ESRD) in HIV positive patients in the US Veterans Association (VA) cohort
Associations between tenofovir use and renal complications in VA cohort
Other news
ACT-UP at 25: tax Wall Street, end AIDS
PDFs
Volume 13 Number 5/6 May/June 2012 PDF
HTB RSS
Early access
Updated treatment guides
5 December 2024
All early access reports
Current issues
December 2024
November 2024
October 2024
Back issues
Special report
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate